Scientists have a deep understanding of the strengths and shortcomings of research models, which gives them insight when validating new compounds. This has ultimately helped lead the charge in developing more complex models for neuroscience research. Patrick Sweeney from Charles River discusses in GEN.
A 2013 study reported that only 43% of cell lines could be uniquely identified, indicating that cell line authentication is crucial to understanding and documenting materials used in biopharmaceutical production. Dr. Debbie Letham from Charles River discusses in GEN.
Researchers are teaching mice to nose-poke a touchscreen by doling out strawberry milkshakes as part of cognitive testing, a technique they hope will help in the development in translational therapies for diseases like Alzheimer’s. Maksym Kopanitsa, Head of Translational Biology, discusses the concept in Science.
It is a commonly encountered view from the quantitative bioanalysis community that high resolution mass spectrometry (HRMS) is a qualitative technique employed by biotransformation chemists working in “the other” mass spectrometry laboratory. Read more from Iain Love of Charles River in BioAnalysis Zone.
Despite great progress, most newly developed anticancer agents fail clinical trials, mainly due to the use of inappropriate preclinical models. In this context, patient-derived-xenograft (PDX) models has regained interest over the last decade. Vincent Vuaroqueaux, Ph.D. from Charles River discusses in GEN.
Recently, there has been a push in cancer research to establish and characterize large collections of patient-derived tumor xenograft (PDX) models—mice implanted with cancerous tissue from human patients. Learn more from Julia Schueler, DVM, PhD, and Head of In Vivo Operations at Charles River.
In modern history, endotoxin testing has improved the safety of drugs and medical devices around the world, and the horseshoe crab has been a vital part of that improvement. John Dubczak, General Manager of Charles River's Microbial Solutions Division, discusses in Outsourced Pharma.
The rapid progression of biosimilar candidates in development pipelines has led to an increase in biosimilar outsourcing. Niall Dinwoodie, Global Coordinator of Charles River's Analytical Testing, spoke to BioProcess International about trends in this emerging space.
In an exclusive interview, CNBC’s Jim Cramer spoke with James Foster, chairman, president and CEO of Charles River Laboratories, about the Company’s growth plans, drug prices and the future of cancer research.
Charles River Laboratories is the first full-service contract research organization (CRO) to join the U.K.-based, international Milner Therapeutics Institute and Consortium. The Milner Therapeutics Institute and Consortium is a collaborative matchmaking service established in 2015 that connects academic research centers, pharmaceutical companies and the industry’s leading scientists in an effort to accelerate research and improve outcomes for patients.